top of page

Changing Treatment Paradigms for Solid
Tumors with Live Biopharmaceutical (LBP) Technology

Delivering hope to patients with

advanced pancreatic cancer and

other aggressive solid tumors.

Loving Couple

Saltikva 

Saltikva  is our lead program in patients with Stage 4, metastatic pancreatic cancer. The Phase 2 results showed that Saltikva  was able to reduce tumor markers, tumor burden, and increase Progression Free Survival and Overall Survival when administered with modified FOLFIRINOX. No serious adverse reactions were caused by Saltikva  in the clinical study.

​​

Saltikva  will soon enter advanced clinical studies in pancreatic cancer and other aggressive solid tumors. 

Screenshot 2025-03-06 at 7.22.28 PM.png
Screenshot 2025-03-06 at 7.22.28 PM.png

Testimonials

Novel Mechanism, Oral Delivery

Over 20 years of research, we believe that we have developed a safe vector to deliver the micro-factory for the production of cytokines within the tumor. The production of target drugs intra-tumorally avoids potential complications and toxicity associated with the systemic administration of the same cytokines. Additionally, our LBP vectors have been shown in animal studies to cause tumor destruction by two other, recognized modes of action, rendering our technology both safe and effective. And yes, Saltikva is orally administered.

Smiling doctor portrait

Our Pipeline is focused on critical, clinical needs.

image.png

Testimonials

March 2025

Saltikva Patient Interview 

Behind every therapy is a story.

This is one of them.​

Saltikva Patient Testimonial

Compassionate Care Patient

“When diagnosed, I did not want very toxic treatments leading to a little more time feeling rotten before dying…. Saltikva  is sort of like taking Lipitor, you’ll likely have a good life for longer…”

Regulatory &
Expanded Access

Saltikva   is not yet an approved pharmaceutical product. Salspera is currently planning pivotal trials for approval purposes.

​

Saltikva  has been awarded Orphan Drug and Fast Track Designations in pancreatic cancer by the US FDA.

​

Salspera will consider all compassionate care requests under Expanded Access, depending on the review of patient criteria and other factors such as drug availability.

​

Salspera Osteosarcoma Program was awarded Orphan Drug Designation by US FDA.

​

Screenshot 2025-03-06 at 7.22.28 PM.png
Screenshot 2025-03-06 at 7.22.28 PM.png

Leadership

Salspera is managed by an expert team along with a Medical Advisory Panel and Business Advisory Panel.

​

Salspera is opperationally supported by external advisors, consultants and service providers to professionally manage the development of the technology, products and the business.

Screenshot 2025-03-06 at 10.59.07 PM.png

Eddie Moradian, PHD

Chief Executive Officer, Co-Founder

 

  • Seasoned executive having founded / co-founded 10 biotech companies over 30 years.

  • Experienced investor and operational chief executive of biotech companies involved in the life science research and early-stage drug development sectors.

  • Founder of numerous companies from conception to market and maturity.

  • Extensive experience in bringing advanced R&D to market.

  • PhD, Swiss Federal Institute of Technology in Zurich, Switzerland.

Screenshot 2025-03-06 at 10.59.07 PM.png
Screenshot 2025-03-06 at 10.57.06 PM.png

Daniel Saltzman, MD, PhD

Chief Medical Officer, Co-Founder

​

  • Originator of the technology platform, which is the basis of Salspera today.

  • Author of 30 publications and 17 presentations on the topic of bacterial therapeutics.

  • Member of the 2017 National Cancer Institute Consensus Conference on Bacterial Based Cancer Therapy, member of the NIH Study Section in 2024, 2026.

  • Chief of Pediatric Surgery, University of Minnesota

  • Earned his MD and PhD degrees from the University of Minnesota.

bottom of page